CA2865642C - Adenoviral tumor diagnostics - Google Patents

Adenoviral tumor diagnostics Download PDF

Info

Publication number
CA2865642C
CA2865642C CA2865642A CA2865642A CA2865642C CA 2865642 C CA2865642 C CA 2865642C CA 2865642 A CA2865642 A CA 2865642A CA 2865642 A CA2865642 A CA 2865642A CA 2865642 C CA2865642 C CA 2865642C
Authority
CA
Canada
Prior art keywords
adenoviral
cancer
tumor diagnostics
patient
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2865642A
Other languages
English (en)
French (fr)
Other versions
CA2865642A1 (en
Inventor
Clodagh O'shea
Colin Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of CA2865642A1 publication Critical patent/CA2865642A1/en
Application granted granted Critical
Publication of CA2865642C publication Critical patent/CA2865642C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10331—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2865642A 2012-03-14 2013-03-14 Adenoviral tumor diagnostics Active CA2865642C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610970P 2012-03-14 2012-03-14
US61/610,970 2012-03-14
PCT/US2013/031646 WO2013138650A1 (en) 2012-03-14 2013-03-14 Adenoviral tumor diagnostics

Publications (2)

Publication Number Publication Date
CA2865642A1 CA2865642A1 (en) 2013-09-19
CA2865642C true CA2865642C (en) 2021-10-26

Family

ID=49161824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865642A Active CA2865642C (en) 2012-03-14 2013-03-14 Adenoviral tumor diagnostics

Country Status (8)

Country Link
US (2) US9885090B2 (https=)
EP (1) EP2825889A4 (https=)
JP (1) JP6329936B2 (https=)
CN (2) CN104204805B (https=)
AU (1) AU2013231972B2 (https=)
CA (1) CA2865642C (https=)
IN (1) IN2014DN06898A (https=)
WO (1) WO2013138650A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
GB201418965D0 (https=) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US9880150B2 (en) 2015-01-28 2018-01-30 Thomas Jefferson University E2F reporter melanoma cells
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
KR102341644B1 (ko) * 2015-08-04 2021-12-21 삼성디스플레이 주식회사 액정 표시 장치 및 그 제조방법
EP3359175B1 (en) 2015-10-05 2020-09-16 Salk Institute for Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
CA3041517A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
KR102080996B1 (ko) * 2018-07-23 2020-02-25 주식회사 코어파마 암세포 특이적 아데노바이러스
JP7273987B2 (ja) * 2019-10-25 2023-05-15 株式会社東芝 腫瘍細胞群の特性を決定する方法、キット及びプログラム

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226602B1 (en) 1998-10-15 2009-04-28 Canji Selectively replicating viral vectors, pharmaceutical preparations containing them and process for producing them
EP1593742A3 (en) * 1999-06-01 2006-02-01 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
AU5464000A (en) * 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2002079507A2 (de) * 2001-04-02 2002-10-10 Bayer Aktiengesellschaft Verfahren zur spezifischen detektion, isolation und charakterisierung von zellen aus körperproben durch transfektion von nukleinsäurekonstrukten
CN100475966C (zh) * 2001-11-23 2009-04-08 上海三维生物技术有限公司 具有肿瘤细胞特异性感染和转基因表达能力的新型腺病毒
EP1545627A4 (en) * 2002-10-01 2006-12-27 Univ Duke TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
CN1424401A (zh) * 2003-01-06 2003-06-18 李川源 有条件复制型腺病毒及其构建方法和用途
AU2004272747A1 (en) * 2003-09-18 2005-03-24 Genmab A/S Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US7943373B2 (en) * 2004-09-29 2011-05-17 Oncolys Biopharma, Inc. Telomelysin/GFP-expressing recombinant virus
RU2007119313A (ru) 2004-10-25 2008-11-27 Новартис АГ (CH) Полинуклеотиды и полипептиды torc и способы применения
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
KR100723009B1 (ko) * 2005-11-30 2007-05-29 한국원자력연구원 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물
US20080242608A1 (en) * 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
US9261508B2 (en) * 2008-04-25 2016-02-16 Istituto Superiore Di Sanita Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
JP5596026B2 (ja) * 2008-06-19 2014-09-24 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用
KR101034811B1 (ko) * 2008-08-25 2011-05-16 단국대학교 산학협력단 조직 특이적 프로모터와 암 특이 유전자를 타겟팅하는트랜스-스플라이싱 라이보자임을 포함하는 재조합아데노바이러스 및 이의 용도
CN102191245B (zh) * 2010-03-15 2013-11-13 浙江东方基因生物制品有限公司 应用肿瘤特异性启动子表达报告基因来检测循环血中肿瘤细胞的方法和试剂
US20140017668A1 (en) * 2010-06-30 2014-01-16 The Johns Hopkins University COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING CIRCULATING TUMOR CELLS (CTCs)
WO2012024351A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method

Also Published As

Publication number Publication date
JP6329936B2 (ja) 2018-05-23
WO2013138650A1 (en) 2013-09-19
CN107267554A (zh) 2017-10-20
US9885090B2 (en) 2018-02-06
CN104204805A (zh) 2014-12-10
AU2013231972B2 (en) 2018-03-22
CA2865642A1 (en) 2013-09-19
JP2015512507A (ja) 2015-04-27
AU2013231972A1 (en) 2014-10-02
CN104204805B (zh) 2017-08-01
EP2825889A4 (en) 2015-10-28
US20180100204A1 (en) 2018-04-12
EP2825889A1 (en) 2015-01-21
IN2014DN06898A (https=) 2015-05-15
US20150005397A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
CA2865642C (en) Adenoviral tumor diagnostics
IL275874A (en) Therapeutic use of adenovirus
EP3525168C0 (en) VIRTUAL CEPHALOMETRIC IMAGING
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
WO2012158780A3 (en) Lung cancer signature
EP2831280A4 (en) PROCESS FOR THE PROGNOSIS, DIAGNOSIS AND TREATMENT OF IDIOPATHIC LUNG FIBROSIS
ZA201504663B (en) Compositions and methods for diagnosing thyroid tumors
HUE049886T2 (hu) Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
GB2509193B (en) Dual-Modality Mammography
EP2897631A4 (en) TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
IL222605A0 (en) Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes
HRP20181726T1 (hr) Neinvazivno dijagnosticiranje raka
LT3011975T (lt) Kietoji kompozicija, skirta dažiklio vartojimui per burną ir jos diagnostinis panaudojimas
EP2659826A4 (en) Endoscopic diagnosis apparatus
EP2922564A4 (en) ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS
EP2637671A4 (en) CARDIAC GLYCOSIDE ANALOGUES IN COMBINATION WITH EMODINE FOR THE TREATMENT OF CANCER
WO2012044684A3 (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
EP2663220A1 (en) Virtual endoscopic imaging with high risk structure highlighting
BR112013014811A2 (pt) composição de tratamento de pano
ZA201501441B (en) Mammographic tomography test phantom
EP2927686A4 (en) AUTOMATIC IN VITRO DIAGNOSTIC APPARATUS INCLUDING INCLINE ROTARY AGITATOR
EP2841100A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF MYOCARDIAL ACUTE INFARCTION
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2012012689A3 (en) Circulating micrornas are biomarkers of various diseases
EP2772255A4 (en) COMPOSITION WITH SYRINGARESINOL TO IMPROVE THE SKIN

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180313

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260302

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260302